1 / 30

Menopause and Hormone Therapy

Menopause and Hormone Therapy. Jennifer O. Howell, MD Women’s Primary Healthcare Division UNC OB/GYN. Objectives. evaluate and treat menopause/perimenopausal conditions, including the use of lifestyle modifications and hormone replacement therapy

derick
Télécharger la présentation

Menopause and Hormone Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Menopause and Hormone Therapy Jennifer O. Howell, MD Women’s Primary Healthcare Division UNC OB/GYN

  2. Objectives • evaluate and treat menopause/perimenopausal conditions, including the use of lifestyle modifications and hormone replacement therapy • identify and screen patients at risk for osteoporosis • review calcium/Vitamin D supplementation for prevention of fractures in postmenopausal women • describe long-term follow-up necessary for menopausal patients • describe indications/contraindications for treating patients with HT

  3. Menopause • Definition: 12 months of amenorrhea; average age is 51 • Perimenopause – “around the menopause” – later part of the menopausal transition  first 5 yrs after menopause • Menopausal transition • Variable cycle length - early • Skipped menses - later • Vasomotor symptoms -later

  4. Menopausal health issues Well-woman exam in a 57 yo – sees internist only when sick • Osteoporosis screening • Mammography – ACOG 2011: yearly from 40 on • Cardiovascular risk factor assessment • Colon cancer screening – Colonoscopy q 10yrs @ age 50 • Thyroid screening – can consider age >50 • Vaccines (flu qyr;Td q10yrs; pneumococcus 1x age>65) • Depression screening

  5. Osteoporosis • Prevention • Calcium – diet and supplement = 1200mg/day • Vitamin D – 800 IU • Weight-bearing exercise • Screening – DEXA scans Age >65, consider for patients between 50-65 if RF: • Long-term Glucocorticoid therapy • Low body weight (<127lbs) • FH of hip fracture • Cigarette smoking • Excess alcohol intake • How often to screen?

  6. DEXA scans – quick tutorial • Dual energy xrayabsorptiometry • Measures bone mineral content in grams ÷ bone area = Bone mineral density (BMD – g/cm2) • Typically measures Hip and Lumbar spine BMD • T-score = patient’s BMD – mean value of young-adult reference population ÷ SD of YA population • This value used to diagnose osteoporosis in peri/post menopausal women • Z-score compares patients BMD to a population of peers • This value for premenopausal patients

  7. T score = -1.0 – -2.4 T-score ≤ -2.5

  8. Osteoporosis – the FRAX tool • NOF (national osteoporosis foundation) recommends tx of postmenopausal women w/ H/O vertebral/hip fracture or with Osteoporosis based on T-score. • What about Osteopenic patients? Use the FRAX tool • Uses BMD at the hip, FH, age, BMI, habits, ethnicity, country to calculate 10yr fracture risk • Consider tx for patients whose 10 yr risk of major osteoporotic fracture exceeds 20% • http://www.shef.ac.uk/FRAX/index.jsp

  9. Pharmacologic Tx - osteoporosis • R/O secondary osteoporosis, especially in young patients • Labs – Ca, Phosphorous, Cr, CBC, 25-hydroxy Vit D • Cancer, multiple myeloma, hyperparathyroidism Bisphosphonates - Inhibit bone resorption • Aledronate (Fosomax) 70mg weekly same fx • Risedronate (Actonel) 35mg weekly data • Ibandronate (Boniva) 150mg monthly (no hip fx data) • IV Zoledronic Acid (Reclast) yearly

  10. BisphosphonatesWhat else do I need to know? • Contraindications – Upper GI disease, renal insufficiency • How to take? Empty stomach, first thing in am, 80z water, no food or drink and stay upright for 30min & make sure getting adequate Ca & Vit D • “I saw on the news . . .̋ • ONJ – 1/10,000-1/100,000; mostly on IV therapy, cancer, dental work, poor dentition • Musculoskeletal pain, Afib, long-term use and atypical fx • Check response to therapy ~2yrs repeat DEXA; consider “drug holiday” after 5 years.

  11. Raloxifene (Evista) • SERM – 60mg/daily, oral • Strong agonist at the bone • Strong antagonist at the Breast • No effect on endometruim • Usually worsens vasomotor sx • Same VTE risk as Estrogen • Reasonable alternative to Bisphos. in intolerant patients • Good prevention indication; not as good treatment option in terms of BMD/fracture data • Consider in pts with FH Breast CA

  12. Menopausal Sx • Bleeding patterns • Hot flushes • Sleep disturbance • Vaginal dryness • Sexual dysfunction • Irritative urinary sx • Depression/anxiety • Breast pain • Menstrual migraines • Joint pain/skin changes

  13. Treatmentof Menopausal Sx • Over the counter options • Non Hormonal pharmacological options • Hormone therapy

  14. Herbal Remedies for Vasomotor Sx - phytoestrogens Isoflavones • Soy: -double blind, crossover study in Br cancer pts – no effect; more pts preferred placebo -meta-analysis of 11 studies – negative results • Red Clover: (promensil) -meta-analysis of 6 trials – all negative results Lignans • Flaxseed -several trials, small numbers; trend toward reduction in hot flashes -double-blind, placebo-controlled RCT presented in 2011 – No effect

  15. Herbal remedies for Vasomotor Sx • Black Cohosh–no effect in RCT and safety concerns • Vitamin E- weak results in RCT, and patients did not prefer in cross-over studies • DHEA- positive results in 2 small trials, not confirmed with RCT • Evening Primrose Oil- no effect in RCT • Dong Quai-no effect in RCT, estrogen-like effect so safety concern in breast cancer patients • Ginseng-no effect in RCT • Wild Yam – no effect in RCT& progestational

  16. Non-Hormonal Options –Vasomotor sx *results only on crossover arm (Bordeleau, Clinical Therapeutics/Vol 29, #2, 2007)

  17. Treatment - HT • Contraindications: known CHD, breast cancer, previous thromboembolic event or CVA, active liver disease • HERS data (1998) – RCT, Prempro, av. age 67, did not prevent heart disease; increase VTE • WHI data (2002) RCT, halted early – Prempro; average age 65; extra 8 cases per 10,000 w.yrs of MI & breast cancer; increased VTE risk, decreased risk of colon cancer, osteoporotic fractures; estrogen –only arm?

  18. ACOG’s thoughts . . . • HT is effective and FDA-approved for the relief of menopausal symptoms such as hot flashes. • Although HT is effective for prevention of postmenopausal osteoporosis, consider non-estrogen medications first if osteoporosis prevention is the sole reason for using HT. • HT should not be used for the prevention of heart disease. • Although the WHI study of HT used a specific prescription product [Prempro, estrogen plus progestin], absent further data it should not be assumed that the risks would be different for any other hormone therapies or products.

  19. NAMS position statement • HT is the most effective treatment for menopause related vasomotor symptoms = primary indication for HT • Lowest effective doses • Limited to transition years • Full discussion of R&B especially if considering long-term use

  20. Hormone Therapy • 49yo P2 LMP: 2 months ago c/o intermittent hot flushes, vaginal dryness, emotional lability and severe PMS in the setting of extreme cycle variability q21-60 days. • BMI 22, normal exam except mild loss of rugations on speculum exam • mild HTN on HCTZ; on Zoloft for years for dysthymia; FH positive for MI and DM in mother age 65, postmenopausal breast cancer in MGM • married; 2 teenagers; wine @ night, non-smoker

  21. What to do? • Low-dose OCP’s • HT • Combined cyclic – estrogen every day and progestin x 14 days of month (peri or early menopausal; +withdrawal bleed) • Combined continuous – E&Pevery day (later postmenopausal, possible BTB 3-6months) Consider baseline endometrial biopsy and/or if BTB persists

  22. Types of Estrogens • Oral vs. Transdermal – ?less VTE with transdermal • Equivalents: 1mg of estradiol = 50mcg/day of estradiol patch=0.625mg conjugated EE(Premarin)=0.75mg esterified estrogen (Ogen)=5mcg ethinylestradiol Tips: “Low dose” E2 – 0.3-0.5mg (.025mcg/d patch) may be sufficient Unopposed estrogen can often be useful especially premenstrually in perimenop. woman; short term only as a “test dose” Treat vaginal atrophy only with local vs. systemic estrogen.

  23. Vaginal Estrogens – dosing & absorption • Estradiol tablet (Vagifem) • 10 mcg - 3 to 11 pg/mL serum estradiol • Low dose estradiol ring (Estring) • 7.5 mcg/day - 5 to 10 pg/mL serum estradiol • Conjugated estrogens cream (Premarin) • 1 g of cream = 0.625 mg conjugated estrogens • Estradiol cream (Estrace) • 1 g of cream = 100 mcg estradiol; 200 mcg of estradiol cream results in a serum estradiol level of approximately 40 pg/mL

  24. Vaginal Estrogens - Regimens • Estradiol ring (Estring) – q 3months • Estradiol tablets – qhsx2weeks, then 2-3x/week • Creams – long term you want no more than 50mcg estradiol; o.3conjugated estrogens = ½ gram cream. • 1g (1/2 applicator full) qhs x2 weeks, ½ -1g q2-3nights week • Applicators are often 2g applicators so many people write prescriptions based on this; confusing, safer to specify grams. • Not necessary for routine P4 withdrawal; can consider qyr as a test.

  25. Types of Progestin • Mostly oral (with few exceptions) • MPA 5-10mg day=cyclic dosing; 2.5mg combined • Micronized progesterone (Prometrium) 200mg cyclic; 100-200mg combined • Norithindrone (Aygestin) 5mg cyclic, .5-1mg combined • Drospiredone Alternate progestin regimens – quarterly, Levonorgestrel IUD – data lacking; but an option with disclosure to patients and +/- endometrial sampling.

  26. Products (I have no conflict of interest ) Combined products – Oral: Prempro – CEE/MPA (several different doses .625/2.5; .625/5; .45/1.25, .3/1.5) FemHRT -5mcg ethinyl estradiol/1mg norithindrone (2.5/0.5) Prefest- 1mg estradiol/0.9 norgestimate Activella – 1mg estradiol/0.5mg norithindrone Angelique – 1mg estrdiol/0.5mg drospirenone Transdermal: ClimaraPro - .045mcg E/.015 levonorg., Combipatch.05/1.25norethindrone

  27. Products (I have no conflict of interest ) • Systemic Estrogens • Patches all estradiol in varying doses – (Climara, Vivelle, generic); Menostar - .014mcg approved for prevention of osteoporosis, twice yrly P4 – not well-studied; works for hot flushes in some women • Oral – CEE, CSE, estradiol, esterified estrogens • Vaginal – FemRing (50 or 100mcg estradiol q 3months) • Emulsions, Gels, Sprays: (Estrasorb; Divigel, Estrogel, Elestrin; Evamyst) – watch for unintentional exposure in kids and pets

  28. Others Estrogen & Testosterone combinations (Estratest, generic) • 1.25mg estrogen/2.5 methyltestosterone or HS version (half-stregnth) 0.625/1.25 Bio-identical Hormone replacement – What is this?

  29. The End! Questions?

More Related